Summary
43 / 100 · Bulios Score
Valuation 47Growth 83Profitability 11Quality 6Debt 67Stability 63
What speaks for it
- Revenue grew by 16% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (SEK)
2021202220232024202520262027
Diluted EPS (SEK)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 30% a year over 5 years. Over the last 3 years it grew by 16% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of 127.1M kr.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments 3.54M kr
Debt 50.9M kr
Free cash flow over 12 months -57.5M kr
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.